Plerifor

Plerifor

plerixafor

Manufacturer:

Camber

Distributor:

Camber
Concise Prescribing Info
Contents
Plerixafor
Indications/Uses
In combination w/ granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection & subsequent autologous transplantation in patients w/ non-Hodgkin's lymphoma (NHL) & multiple myeloma.
Dosage/Direction for Use
0.24 mg/kg SC approx 11 hr prior to initiation of each apheresis following 4 days of pre-treatment of G-CSF. Max: 40 mg/day. Concomitant therapy: Administer G-CSF 10 mcg/kg daily every morning for 4 days prior to the 1st evening dose of Plerifor & on each day prior to apheresis. Patients w/ renal impairment CrCl ≤50 mL/min 0.16 mg/kg once daily. Max: 27 mg/day, CrCl >50 mL/min 0.24 mg/kg once daily. Max: 40 mg/day.
Contraindications
Special Precautions
Not for HSC mobilization & harvest in patients w/ leukemia. Monitor WBC & platelet during treatment. Potential reinfusion of tumor cells. Evaluate patients w/ left upper abdominal pain &/or scapular or shoulder pain for splenic integrity. Observe patients for signs & symptoms of hypersensitivity during & after administration for at least 30 min & until clinically stable. Moderate & severe renal impairment (CrCl ≤50 mL/min). Pregnancy & lactation. Childn.
Adverse Reactions
Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness & vomiting; insomnia, flatulence.
Drug Interactions
Increased serum conc w/ drugs that reduce renal function or compete for active tubular secretion.
ATC Classification
L03AX16 - plerixafor ; Belongs to the class of other immunostimulants.
Presentation/Packing
Form
Plerifor inj 24 mg/1.2 mL
Packing/Price
2 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in